News | Implantable Cardiac Monitor (ICM) | July 07, 2020

Next Generation Medtronic ICM Offers Remote Programming and Improved Longevity

Linq II system allows continuous cardiac monitoring for 4.5 years

The Linq II implantable cardiac monitor (ICM) system delivers improved device longevity compared to other ICMs and enhanced accuracy to correctly detect abnormal heart rhythms, simplifying the diagnosis and monitoring of patients. The new devices allows continuous cardiac monitoring for up to 4.5 years.

The Linq II implantable cardiac monitor (ICM) system delivers improved device longevity compared to other ICMs and enhanced accuracy to correctly detect abnormal heart rhythms, simplifying the diagnosis and monitoring of patients. The new devices allows continuous cardiac monitoring for up to 4.5 years.


July 7, 2020 – Medtronic announced it received U.S. Food and Drug Administration (FDA) clearance and European CE mark approval for its Linq II insertable cardiac monitor (ICM) with remote programming, which enables clinicians to optimize device settings without the need for patients to return to the office or hospital. The Linq II system also delivers improved device longevity compared to other ICMs and enhanced accuracy to correctly detect abnormal heart rhythms, simplifying the diagnosis and monitoring of patients. The new devices allows continuous cardiac monitoring for 4.5 years using nominal settings.[1]

Linq II is a small (one-third the size of a AAA battery), wireless ICM for patients with abnormal heart rhythms who experience infrequent symptoms including dizziness, palpitations, syncope (fainting) and chest pain, thereby requiring long-term monitoring or ongoing management. The device will be commercially available in the U.S. and Europe later this summer.

“In the current COVID-19 environment, the Linq II system offers patients a seamless way to experience ongoing connectivity between their device and their physician, while reducing the need for in-office visits,” said Rob Kowal, M.D., Ph.D., chief medical officer of the Cardiac Rhythm and Heart Failure division, which is part of the Cardiac and Vascular Group at Medtronic. “Linq II gives physicians actionable data to help diagnose underlying heart conditions and define treatment protocols for patients with atrial fibrillation (AF) or other abnormal heart rhythms.”

The Linq II device incorporates many of the features of Linq with TruRhythm plus improvements that differentiate the device from other ICMs:
   • Accuracy and Streamlined Workflows: The Linq II device has the lowest published rates of AF false detections compared to previous ICMs.[2-5] It also has an industry exclusive premature ventricular contraction (PVC) detector to help with patient diagnosis; PVCs are extra, abnormal heartbeats that begin in the ventricles, and disrupt the heart rhythm. Additionally, clinicians spend 33 percent less time reviewing ICM transmissions,[6] resulting in potential office efficiencies and reduced costs due to more streamlined workflows.
   • Remote Programming: The Linq II ICM offers remote programming, which reduces the need for patients to come into the office to have their device settings adjusted – a benefit for both patients and physicians, especially during the current COVID-19 pandemic.
   • Remote Patient Management: Patients with the Linq II ICM can choose one of two monitoring options to fit their lifestyles and increase remote monitoring compliance, potentially leading to improved patient outcomes.
   • Patients can use their smartphones to automatically transfer device data via the MyCareLink Heart mobile app using BlueSync technology that
enables secure communication via Bluetooth.
   • Patients who are unable or prefer not to use a cell phone can transmit device data with the MyCareLink Relay Home Communicator.
   • Increased Longevity: The Linq II device offers an extended duration of continuous monitoring at 4.5 years using nominal settings.[1] Continuous monitoring gives physicians greater insights into patient data, aids in diagnoses and helps them manage chronic cardiac arrhythmias.

For more information: www.medtronic.com

References:
1. Linq II Clinician Manual. M974764A001.
2 BiotronikBioMonitor 2 Technical Manual. 2017.
3. NölkerG, et al. J Cardiovasc Electrophysiol. 2016;27:1403-1410. 
4. Confirm Rx ICM DM3500 FDA Clearance Letter. 2017.
5. PürerfellnerH, et al. Europace. 2018;20:f321-f328 
6. Alert Analysis for Linq II with TruRhythm and Linq II, Medtronic data on file, 2020.

 


Related Content

Case Study | Implantable Cardiac Monitor (ICM)

Every second counts when someone is having a stroke and immediate care can mean the difference between life and death ...

Home July 02, 2025
Home
News | Implantable Cardiac Monitor (ICM)

July 11, 2024 — Dr. Fadi Mansour performed the first Canadian implant of BIOTRONIK’s newest pacemaker and CRT-P ...

Home July 11, 2024
Home
News | Implantable Cardiac Monitor (ICM)

October 3, 2023 -- Boston Scientific launched the LUX-Dx II+ Insertable Cardiac Monitor (ICM) System, a next-generation ...

Home October 03, 2023
Home
Feature | Implantable Cardiac Monitor (ICM)

The global cardiovascular diagnostic and monitoring devices market was valued at $14.2B in 2021 and is projected to ...

Home June 13, 2023
Home
News | Implantable Cardiac Monitor (ICM)

May 18, 2023 — Abbott announced its Assert-IQ insertable cardiac monitor (ICM) has received U.S. Food and Drug ...

Home May 18, 2023
Home
News | Implantable Cardiac Monitor (ICM)

May 4, 2023 — Avertix Medical, Inc., formerly known as Angel Medical Systems, Inc., a company focused on improving long ...

Home May 04, 2023
Home
News | Implantable Cardiac Monitor (ICM)
April 29, 2022 – Medtronic has announced new data from the STROKE AF clinical trial, which showed that large and small ...
Home April 29, 2022
Home
News | Implantable Cardiac Monitor (ICM)
April 6, 2022 – Final results from the BIO|GUARD-MI study show a 31 percent reduction of MACE in a sub-group analysis of ...
Home April 06, 2022
Home
News | Implantable Cardiac Monitor (ICM)

September 7, 2021 — Remote monitoring of implantable cardiac monitors (ICMs) is highly effective for early detection of ...

Home September 07, 2021
Home
News | Implantable Cardiac Monitor (ICM)

August 9, 2021 - In association with Heart Rhythm 2021, Biotronik today announced that the latest implantable cardiac ...

Home August 09, 2021
Home
Subscribe Now